Waiver of pre-emptive rights. The Subscriber hereby grants, conveys and vests unto the President of the Company, or unto such other nominee or nominees of the President as he may determine from time to time, in the President’s sole and absolute discretion, to the extent permitted by law, the right to act as the Subscriber’s power of attorney solely for the purpose of waiving any prior or pre-emptive rights which the Subscriber may have to further issues of equity or debt by the Company under applicable corporate and securities laws.
Waiver of pre-emptive rights. Each Seller, by its execution of this Agreement, consents to the sale and purchase contemplated by clause 2.1 and irrevocably waives in favour of the Buyer any rights of pre-emption that that Seller has, or may have, in respect of the Shares, whether conferred by the constitution of the Company or otherwise.
Waiver of pre-emptive rights. The Seller shall waive any right of first refusal for the purchase of, or any pre-emptive rights with respect to, the sale and transfer of the any participation interests in the Company as contemplated by the Transaction Documents, including, but not limited to, waivers with regard to the Concurrent Purchase Agreements, and shall grant waivers with regard to the TDC Option Agreement and the Ukrtelecom Option Agreement, in each case substantially in the form of Exhibit F hereto.
Waiver of pre-emptive rights. The Corporation shall have received ---------------------------- written waivers of the rights triggered by the offer and sale of the Shares under the letter to Glyko BioMedical Ltd. ("Glyko") dated June 27, 1997, regarding certain pre-emptive rights dated June 27, 1997 (the "Glyko Pre-emptive Rights Letter") and under the letter to BB BioVentures L.P., dated December 30, 1997, regarding certain pre-emptive rights (the "BB BioVentures Pre-emptive Rights Letter").
Waiver of pre-emptive rights. The Corporation shall have received ---------------------------- written waivers of the rights triggered by the offer and sale of the Shares under the Glyko Pre-emptive Rights Letter and the BB BioVentures Pre-emptive Rights Letter by the respective parties thereto.
Waiver of pre-emptive rights. Each Investor who is a party to the Restated Rights Agreement hereby waives the Right of First Refusal (as defined in the Restated Rights Agreement), any pro rata allocation rights and any notice requirements set forth in Section 4 of the Restated Rights Agreement in connection with the offer, sale and issuance of the Series E Preferred Stock.
Waiver of pre-emptive rights. The Company shall have received ---------------------------- written waivers of the rights triggered by the offer and sale of the Notes and the shares of Common Stock issuable upon conversion thereof under: (i) the letter to Glyko BioMedical Ltd. dated June 27, 1997, regarding certain pre- emptive rights (the "GLYKO PRE-EMPTIVE RIGHTS LETTER"), (ii) the letter to Genzyme Corporation dated September 4, 1998 regarding certain pre-emptive rights (the "GENZYME PRE-EMPTIVE RIGHTS LETTER"), and (iii) the letter to BB BioVentures L.P., dated December 30, 1997, regarding certain pre-emptive rights (the "BB BIOVENTURES PRE-EMPTIVE RIGHTS LETTER").
Waiver of pre-emptive rights. The Vendor waives in favour of the Purchaser any rights of pre-emption which the Vendor or a Related Body Corporate of it has or may have in respect of any of the Shares.
Waiver of pre-emptive rights. Each of THL and THL-CCI hereby agrees to waive any existing pre-emptive rights it may have in connection with any Shares owned beneficially or of record by it pursuant to Section 3.1(b) of the Investors Agreement dated February 3, 1995, between the Corporation, THL and THL-CCI (the "1995 Investors Agreement") and Section 3.1(h) of the 1995 Shareholders Agreement.
Waiver of pre-emptive rights. The Purchaser hereby waives, effective as of the Closing Date, any and all preemptive rights granted under Section 2.1 of the Investor Rights Agreement with respect to the issuance and sale by the Company of (i) the Preferred Stock and Warrants pursuant to this Agreement and the issuance of Underlying Shares upon exercise of the Warrants, and (ii) the issuance of up to 200,000,000 shares of Common Stock, 5,196,300 shares of Series A cumulative preferred stock, par value $0.001 per share, liquidation preference $100.00 per share and warrants to purchase up to an aggregate of 86,605,174 shares of Common Stock pursuant to the Underwriting Agreement and the issuance of shares of Common Stock upon the exercise of such warrants in accordance with the terms thereof.
